HomeCompareAZRX vs ORCC

AZRX vs ORCC: Dividend Comparison 2026

AZRX yields 57.97% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AZRX wins by $568.1K in total portfolio value
10 years
AZRX
AZRX
● Live price
57.97%
Share price
$3.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$589.5K
Annual income
$134,189.34
Full AZRX calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — AZRX vs ORCC

📍 AZRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAZRXORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AZRX + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AZRX pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AZRX
Annual income on $10K today (after 15% tax)
$4,927.54/yr
After 10yr DRIP, annual income (after tax)
$114,060.94/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, AZRX beats the other by $114,060.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AZRX + ORCC for your $10,000?

AZRX: 50%ORCC: 50%
100% ORCC50/50100% AZRX
Portfolio after 10yr
$305.5K
Annual income
$67,095.19/yr
Blended yield
21.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

AZRX
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
-1.8
Piotroski
6/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AZRX buys
0
ORCC buys
0
No recent congressional trades found for AZRX or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAZRXORCC
Forward yield57.97%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$589.5K$21.4K
Annual income after 10y$134,189.34$1.04
Total dividends collected$485.6K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: AZRX vs ORCC ($10,000, DRIP)

YearAZRX PortfolioAZRX Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$16,497$5,797.10$11,190$489.61+$5.3KAZRX
2$26,590$8,937.89$12,229$256.01+$14.4KAZRX
3$41,915$13,463.51$13,216$130.74+$28.7KAZRX
4$64,683$19,834.65$14,207$66.02+$50.5KAZRX
5$97,818$28,606.69$15,234$33.17+$82.6KAZRX
6$145,096$40,430.56$16,317$16.62+$128.8KAZRX
7$211,301$56,048.29$17,468$8.32+$193.8KAZRX
8$302,374$76,282.53$18,695$4.16+$283.7KAZRX
9$425,560$102,019.99$20,006$2.08+$405.6KAZRX
10$589,539$134,189.34$21,407$1.04+$568.1KAZRX

AZRX vs ORCC: Complete Analysis 2026

AZRXStock

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Full AZRX Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this AZRX vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AZRX vs SCHDAZRX vs JEPIAZRX vs OAZRX vs KOAZRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.